The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FOLFIRI plus bevacizumab (B) as neoadjuvant treatment for potentially resectable colorectal cancer patients (pts) with liver metastasis: A phase II trial.
Guglielmo Nasti
Research Funding - Roche
Alessandro Ottaiano
No relevant relationships to disclose
Carmen Romano
No relevant relationships to disclose
Francesco Izzo
No relevant relationships to disclose
Paolo Delrio
No relevant relationships to disclose
Vittorio Albino
No relevant relationships to disclose
Pasqualina Giordano
No relevant relationships to disclose
Maria Carmela Piccirillo
No relevant relationships to disclose
Gennaro Daniele
No relevant relationships to disclose
Secondino Lastoria
No relevant relationships to disclose
Corradina Caraco
No relevant relationships to disclose
Cecilia Arrichiello
No relevant relationships to disclose
Elisabetta De Lutio
No relevant relationships to disclose
Piera Maiolino
No relevant relationships to disclose
Fabiana Tatangelo
No relevant relationships to disclose
Rosario Vincenzo Iaffaioli
Research Funding - Roche